Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma

Phase 2 Completed 53 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of etoposide plus radiation therapy followed by combination chemotherapy in treating children with newly diagnosed advanced medulloblastoma.

Timeline

Start: 1998-11
Primary completion: 2007-10
Completion: 2008-03

Outcome

Missed primary endpoint

paper CONCLUSION: Five-year EFS did not differ significantly whether, after surgery, patients received chemotherapy before or after radiotherapy. PMID 23857975 ↗

paper Five-year EFS was 66.0% in the CT1 arm and 70.0% in the RT1 arm (P = .54) PMID 23857975 ↗

Publications

Tarbell NJ, Friedman H, Polkinghorn WR, Yock T, Zhou T, Chen Z, Burger P, Barnes P, Kun L. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol. 2013 Aug 10;31(23):2936-41. doi: 10.1200/JCO.2012.43.9984. Epub 2013 Jul 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	—	Intravenous
Subject	Cyclophosphamide	Other / unclassified	—	Intravenous
Subject	Etoposide	Small molecule	35 mg/m2	Oral
Subject	Etoposide	Small molecule	50 mg/m2	Oral
Subject	Vincristine	Small molecule	—	Intravenous
Background	filgrastim	Protein / enzyme biologic	—	Subcutaneous